Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

10 evidence topics · 16 sources

Summary
  • Treatment of progressing desmoid tumors aims to control tumor growth and relieve symptoms. NICE describes it as “non-curative and aims to control tumour growth and alleviate symptoms”, the 2023 consensus update calls for selecting each patient's management strategy to optimize tumor control and enhance quality of life, and Immunome states that treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.
  • Tumor control with varegacestat in RINGSIDE Part B (data cutoff October 7, 2025): PFS of 94% at 1 year and 89% at 2 years with varegacestat, compared with 66% and 57% with placebo; a hazard ratio of 0.16 (95% CI 0.071, 0.375) and a confirmed objective response rate of 56% versus 9% in Immunome's ESMO release; and a median time to response of 8.2 months among varegacestat responders.
  • Symptom outcomes in RINGSIDE Part B: Immunome reports a worst pain difference of more than 2 points from the first evaluation at week 4. At week 48, least-squares mean changes were -1.50 with varegacestat and +0.59 with placebo on the GODDESS TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
  • Treatment duration: median exposure in RINGSIDE Part B was 20.3 months with varegacestat as of October 7, 2025, and median time on treatment in RINGSIDE phase 2 as of April 10, 2024 was 23.1 months in one abstract and 25.4 months in another. Immunome anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
  • Pauses and retreatment: in the NICE appraisal of nirogacestat, clinical experts supported stopping after 2 years if treatment could continue while the tumor was still shrinking or restart if it grew again. The company reported that less than 1% of people in its compassionate use programme continued beyond year 2, and the committee assumed that most patients stop after 2 years. The long-term nirogacestat follow-up publication (Ratan et al. 2025) states that optimal duration and responses after discontinuation are not well defined. The Desmoid Tumor Working Group states that shrinkage can continue after withdrawal, that long-term disease control is achieved in up to 50–70% of patients, and that treatment can be repeated at recurrence.
  • Long-term continuous nirogacestat: in long-term follow-up of participants randomly assigned to nirogacestat, the objective response rate was 34.3%, 41.4%, 44.3%, and 45.7% with up to 1, 2, 3, and 4 years of treatment, with no additional progression or death events after year 2. In the French DeNi real-world study, median treatment duration was 16 months, the 1-year PFS rate was 76.2%, and 38 of 49 participants with baseline pain (78%) reported pain improvement.
Treatment duration, pauses, and retreatment with gamma secretase inhibitors

“The EAG noted that clinical experts broadly supported stopping treatment after 2 years. But it added that this was only if there was flexibility to continue for longer if the tumour was still shrinking, or restart if, for example, the tumour started growing again.” (opens the source at this quote in a new tab)

“The company provided data on tumour size plateaus. It said that by year 2, 100% of tumours had plateaued in people with complete and partial response. In people with stable disease, more than 75% of tumours had plateaued.” (opens the source at this quote in a new tab)

“It recalled that retreatment with nirogacestat was not permitted in De-Fi, so the trial did not provide evidence on restarting treatment after stopping.” (opens the source at this quote in a new tab)

“The company highlighted that based on data from its compassionate use programme (up to April 2025), less than 1% of people having nirogacestat continue treatment beyond year 2.” (opens the source at this quote in a new tab)

“They explained that people in their practice usually stop nirogacestat after about 1 year, very few would continue beyond year 2 and the number of people needing retreatment is low.” (opens the source at this quote in a new tab)

“So, the committee concluded that while it would not recommend a stopping rule, the model should assume that most patients stop treatment after 2 years to align with clinical practice, with a proportion of people continuing or restarting treatment.” (opens the source at this quote in a new tab)